Sponsors (3)
The bill aims to speed and clarify FDA decisions for biosimilar sponsors to accelerate competition and lower drug costs, but it reduces FDA's timing flexibility in ways that could raise safety risks and shift costs onto developers or taxpayers.
Patients who rely on biologic drugs may see lower prices and greater access because faster FDA determinations could speed biosimilar approvals and increase market competition.
Biosimilar sponsors — including small biotech firms and hospital systems — get quicker, clearer regulatory guidance because FDA must notify them by the development-meeting grant date or within 60 days and provide written reasons if it cannot, reducing regulatory uncertainty and improving planning.
Patients and hospitals could face safety risks because tighter limits on FDA timing and authority to require additional studies might allow biosimilars to be approved without complete efficacy or safety data.
Small biosimilar developers may encounter unpredictable or unnecessary study requirements because early forced determinations could push FDA to issue conservative demands to avoid later reversals.
Taxpayers and the FDA could face higher administrative costs if shorter determination windows force reallocation of review resources or faster staffing actions.
Based on analysis of 2 sections of legislative text.
Requires FDA to issue a written determination and meet timing rules before requiring additional clinical studies for biosimilar licensure, applying to 351(k) applications filed after enactment.
Official title: To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
Introduced July 14, 2026 by Nicholas A. Langworthy · Last progress July 14, 2026
Limits when the FDA can require new clinical studies for licensure of a biosimilar product and sets timing rules for notifying applicants. The bill requires the FDA to provide a written determination that additional pharmacodynamic or efficacy studies are necessary either by the time it grants a biosimilar development meeting request (or explains why it cannot yet decide) or, if no meeting occurs or the FDA could not decide earlier, within 60 days after the biosimilar application is submitted. Also makes a minor statutory cleanup by removing one existing subparagraph and renumbering another. The changes apply to biosimilar applications under section 351(k) filed on or after the law’s enactment.